This webpage is intended for UK-I health care professionals.
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Adverse events and product complaint should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard for the UK or www.hpra.ie for Ireland. Adverse events and product complaint should also be reported to Angelini Pharma on (UK) +44 2034889643, (IRE) +353 1 584 4671 or UKIReporting@angelinipharma.com
The latest developments for the use of ONTOZRY® in treatment resistant populations of patients with focal-onset seizures is discussed in this series of videos. Experts in their field discuss their experience of using ONTOZRY® in the real world and what this could mean for eligible patients. These panels were led by UK and US experts.
If you were unable to attend any of the events or would like a refresher of the content, you can catch up with the videos below.